Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.41 |
| ▸ | GABRD | O14764 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRE | P78334 | 2/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27084653 | 0.88 | GPR84 (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5079726 | 0.84 | HDAC1 (0.48) | METAP1ALDH1A1GPR84SLC1A3SLC1A2 | |
| SCHEMBL5079729 | 0.84 | HDAC1 (0.48) | METAP1ALDH1A1GPR84SLC1A3SLC1A2 | |
| SCHEMBL27591715 | 0.82 | GABRP (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5516785 | 0.82 | HDAC1 (0.42) | METAP1ALDH1A1GPR84ADRA1ACHRM1 | |
| SCHEMBL2327830 | 0.81 | METAP1 (0.41) | METAP1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14895463 | 0.81 | TDP1 (0.43) | METAP1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4991474 | 0.79 | METAP1 (0.39) | METAP1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13679380 | 0.78 | GPR84 (0.39) | METAP1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL13403131 | 0.77 | HDAC1 (0.42) | METAP1ALDH1A1GPR84ADRA1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-02-08 | — | — | US | disclosed |
| EP-4199905-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | Oculotherapy, LLC (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023028490-A1 | METHODS OF TREATING PAIN AND USES THEREOF | OCULOTHERAPY, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022040622-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | OCULOTHERAPY, LLC (US) | 2022-02-24 | — | — | WO | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | METAP1 872/4885GABRP 938/4885GABRD 1496/4885 |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | METAP1 1347/4885GABRP 32/4885GABRD 77/4885 |
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | ACHE, PDE6G, PTGES3 | METAP1 748/4885GABRP 1344/4885GABRD 767/4885 |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | METAP1 872/4885GABRP 938/4885GABRD 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.